Please upgrade your browser.
Charity Navigator, the nation's premiere charity evaluator, has awarded the Kidney Cancer Association its coveted 4-star rating for the third consecutive year. Less than 15% of rated charities achieve this distinction.
Linda Irving is concerned about abdominal pains she's had for a few months, and skittish about the four-month wait her sister-in-law endured before recently undergoing kidney cancer surgery.
Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma
On the basis of potential additive or synergistic immunostimulatory antitumor effects, in this phase 1 study, the authors evaluated the combination of sunitinib and tremelimumab (CP675206; an antibody against cytotoxic Tlymphocyteassociated antigen 4 [CTLA4]) in patients with metastatic renal cell carcinoma (mRCC) was evaluated.
Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma
The enhancer of zeste homolog 2 (EZH2) gene exerts oncogenelike activities and its (over)expression has been linked to several human malignancies. Here, authors studied a possible association between EZH2 expression and prognosis in patients with renal cell carcinoma (RCC).
The payments are not illegal and usually not even considered improper.
A positive association between diabetes and kidney cancer has been reported in several investigations.
More than 120 cancer survivors and caregivers, cancer-treating physicians, and patient advocates gathered in San Diego to share their Proleukin® (aldesleukin for injection) treatment experiences.
Consumers previously rejected by insurers or forced to wait six months for coverage because they have costly medical problems are starting to get benefits from a new statewide program for uninsured people.
Researchers led by University of Massachusetts Amherst chemist Vincent Rotello have demonstrated that they can deliver a dormant toxin into a specific site such as a tumor for anti-cancer therapy, then chemically trigger the toxin to de-cloak and attack from within.
There are now emerging data that show the safety and efficacy of this treatment modality in genitourinary malignancies especially in prostate cancer and renal cell carcinoma.
|NeonCRM by Neon One|